Hoth Therapeutics advances HT-KIT: Preclinical success sets stage for human trials and stock market interest

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing precision therapies for unmet medical needs, announced on May 12, 2025, that its experimental antisense oligonucleotide therapy HT-KIT showed robust tumor suppression in preclinical cancer models. The company reported over 80% reduction in KIT expression in vitro and significant tumor growth inhibition in vivo, with no observed systemic toxicity—positioning HT-KIT as a novel, gene-silencing solution for rare, treatment-resistant cancers like gastrointestinal stromal tumors (GIST) and systemic mastocytosis.

The preclinical breakthrough is expected to pave the way for an Investigational New Drug (IND) filing in early 2026 and potentially the initiation of Phase 1 human trials. Hoth’s CEO Robb Knie noted the data underscored HT-KIT’s first-in-class potential to target KIT-driven cancers genetically, rather than relying on traditional small-molecule drugs that can lead to resistance.

What Is HT-KIT and Why It Matters in Precision Oncology

HT-KIT is a proprietary antisense oligonucleotide (ASO) developed by Hoth Therapeutics to bind and silence aberrant KIT mRNA. By preventing translation of the KIT protein—a known oncogenic driver—HT-KIT aims to halt the biological signaling that causes tumor proliferation. This approach differs from existing tyrosine kinase inhibitors (TKIs), which work downstream and often encounter resistance.

KIT mutations are notoriously difficult to treat once secondary mutations emerge, as seen in advanced-stage GIST and mastocytosis patients. TKIs like imatinib and sunitinib have provided short-term disease control but frequently fail due to evolving resistance. HT-KIT’s preemptive strategy—targeting the gene before the protein forms—offers a compelling, resistance-averse mechanism that could expand therapeutic options for patients who have exhausted conventional regimens.

What Did the Preclinical Data Reveal?

In vitro studies demonstrated that HT-KIT reduced KIT gene expression by over 80% in cell lines with activating KIT mutations. Subsequent in vivo models—focused on GIST and mast cell tumors—showed substantial inhibition of tumor growth following systemic HT-KIT administration. Critically, the drug exhibited no off-target toxicity in vital organs, including the liver, kidney, and bone marrow, supporting a favorable safety profile for human trials.

The findings suggest HT-KIT can suppress tumor development at the genetic source while minimizing systemic side effects. This dual benefit makes the therapy particularly attractive for a precision oncology landscape shifting toward mRNA- and DNA-targeted treatments.

When Will Human Clinical Trials Begin?

Hoth Therapeutics expects to file an IND application with the U.S. FDA in early 2026, with a first-in-human Phase 1 clinical trial to follow shortly after approval. The trial will likely involve patients with advanced KIT-mutated tumors, providing initial safety and tolerability data while exploring early signs of efficacy.

To facilitate this next step, the company is in active collaboration with regulatory consultants and contract research organizations. The goal is to fast-track IND readiness while maintaining rigorous preclinical and toxicology testing standards.

How Does HT-KIT Compare to Existing Cancer Therapies?

Current treatment regimens for KIT-driven cancers, such as imatinib and other TKIs, often suffer from off-target effects, limited duration of response, and eventual treatment resistance. These drugs inhibit the activity of the KIT protein post-translation but can be circumvented by secondary mutations in the kinase domain.

HT-KIT, by contrast, works upstream—interfering with mRNA expression to prevent protein synthesis. This upstream mechanism not only reduces the chance of resistance but also allows for a more tailored approach in cancers driven by well-defined genetic mutations. If the Phase 1 trials affirm HT-KIT’s safety and efficacy, it could mark a paradigm shift in targeting genetically defined cancers at the transcriptomic level.

Stock Market Sentiment: How Are Investors Reacting to HOTH?

As of May 12, 2025, Hoth Therapeutics’ stock is trading at approximately $0.9267, reflecting a modest 2.7% decline from the previous close. Intraday trading has been volatile, with share prices swinging between $0.8155 and $1.15, and trading volume nearing 993,000 shares—well above the daily average.

Despite short-term dips, investor sentiment appears cautiously optimistic following the HT-KIT announcement. The company operates in the high-risk, high-reward biotech space, where valuations can swing sharply on preclinical and regulatory news. Analyst ratings lean positive, with two analysts currently maintaining a “Strong Buy” recommendation and a 12-month average price target of $4.50, indicating potential upside of more than 370% from current levels.

However, with projected EPS of -$0.97 for FY2025, the company remains in development mode with no commercial revenues. As such, HOTH is primarily attractive to speculative biotech investors willing to ride the volatility of binary R&D events.

Institutional Sentiment: Who’s Buying (or Selling) HOTH?

Institutional ownership in Hoth Therapeutics is limited, with approximately 3.53% of shares held by institutions, according to recent filings. Key institutional investors include UBS Group AG, Foundations Investment Advisors, LLC, and Two Sigma Investments, LP. However, recent updates indicate a slight decrease in institutional positions, suggesting some degree of caution among large-cap investors.

Given the nature of preclinical-stage biotech companies, it’s common for institutional activity to fluctuate based on anticipated milestones. Many fund managers wait for IND acceptance or Phase 1 readouts before increasing exposure. Retail investors currently dominate trading activity in HOTH, driving much of the recent price swings.

Investment Outlook: Buy, Hold or Wait?

Considering the combination of positive preclinical data, upcoming regulatory milestones, and speculative interest, Hoth Therapeutics may be classified as a “Speculative Buy” for risk-tolerant investors seeking exposure to early-stage oncology innovation. For current shareholders, the sentiment supports a “Hold” recommendation, pending further updates on the IND timeline and Phase 1 trial design.

Investors should watch for key catalysts in the second half of 2025, including final toxicology results, IND-enabling studies, and any partnership or licensing deals that could provide funding or commercial leverage.

Strategic Direction: Where Is Hoth Therapeutics Headed?

Beyond HT-KIT, Hoth Therapeutics is building a diversified pipeline aimed at delivering targeted, patient-centric therapies across oncology, dermatology, and respiratory indications. The company’s focus on antisense technology reflects a broader trend in biotech toward RNA-based therapeutics, which offer greater precision with fewer systemic effects.

Hoth’s business model—centered on early-stage development and licensing—positions it as an innovation engine rather than a commercial heavyweight. This creates opportunities for exit strategies through M&A or out-licensing, especially if HT-KIT shows success in initial human trials. Industry watchers have noted that companies working in rare oncology indications often attract larger partners due to high unmet need and orphan drug incentives.